The oral PI3Kδ inhibitor linperlisib for the treatment of relapsed and/or refractory follicular lymphoma: A phase 2, single-arm, open-label clinical trial.

Tingyu Wang Xiuhua Sun Lihua Qiu Hang Su Junning Cao Zhi-Ming Li Yuqin Song Li Zhang Xiaojian Zhu Huijing Wu Wei Zhang Junmin Li Ke-Shu Zhou Hui Zhou Yu Yang Zhifeng Li Hong Cen Zhen Cai Zhihui Zhang Weijun Fu Jie Jin Fei Li Weixin Wu Xuekui Gu Weiliang Zhu Lihong Liu Zhenjiang Li Shuhua Yi Hanying Bao Zusheng Xu Lugui Qiu

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Linperlisib demonstrated compelling clinical activity and manageable tolerability for relapsed and/or refractory FL patients who had received at least two prior systemic therapies.

Keyphrases

open label
clinical trial
acute lymphoblastic leukemia
acute myeloid leukemia
phase ii
multiple myeloma
hodgkin lymphoma
diffuse large b cell lymphoma
phase iii
phase ii study
study protocol
double blind
randomized controlled trial
squamous cell carcinoma
radiation therapy